HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Intraoperative electron irradiation (IORT) of urologic tumors. Initial results of a pilot study of local recurrences of renal cell cancers].

Abstract
The efficacy of radiotherapy of renal cell carcinomas is limited by its side effects. To avoid gastrointestinal problems the dose must not exceed 45 Gy, but with corresponding protocols no effect has been seen in curative and adjuvant trials. A new three-step protocol combining surgery with intraoperative radiotherapy focussed on the tumor bed fading out the intestine (IORT) and external boost radiotherapy (40 Gy) was used in six patients with local recurrences after tumor nephrectomy. No increase in morbidity was induced by IORT. One year after radiotherapy no recurrences have been seen in the radiation field. We recommend this protocol for patients with solitary local recurrences and for tumors of clinical stage T3 and T4.
AuthorsM Beer, M J Eble, M Wannenmacher, G Staehler
JournalDer Urologe. Ausg. A (Urologe A) Vol. 33 Issue 2 Pg. 110-5 (Mar 1994) ISSN: 0340-2592 [Print] Germany
Vernacular TitleDie intraoperative Elektronenbestrahlung (IORT) bei urologischen Tumoren. Erste Ergebnisse einer Pilotstudie an Lokalrezidiven von Nierenzellkarzinomen.
PMID8178404 (Publication Type: English Abstract, Journal Article)
Topics
  • Adult
  • Aged
  • Carcinoma, Renal Cell (pathology, radiotherapy, surgery)
  • Combined Modality Therapy
  • Electrons (therapeutic use)
  • Female
  • Humans
  • Kidney Neoplasms (pathology, radiotherapy, surgery)
  • Lymphatic Irradiation
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (pathology, radiotherapy, surgery)
  • Neoplasm Staging
  • Nephrectomy
  • Operating Rooms
  • Pilot Projects
  • Radiotherapy Dosage
  • Surgical Equipment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: